277 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES BIOPSY NECRO-INFLAMMATORY SCORES AND ALT NORMALIZATION AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV PATIENTS

276 WEEK 4 HCVRNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV G.V. Matthews, J. Grebely, M. Hellard, B. Yeung, P. Marks, W. Rawlinson, J. Kaldor, G.J. Dore, ATAHC Study Group. National Centre in HIV Epidemiology and Clinical Research (NCHECR), University of New South Wales, Sydney, NSW, Burnet Institute, Melbourne, VIC, Virology Division, SEALS Microbiology, Prince of Wales Hospital, Sydney, NSW, Australia E-mail: gmatthews@nchecr.unsw.edu.au